Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene expression profiling in diffuse large B-cell lymphoma.

Daniel Morgensztern1, Mike G Martin, Izidore S Lossos

  • 1Division of Hematology/Oncology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA.

Leukemia & Lymphoma
|April 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Response to: "Refining Combined-Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma".

American journal of hematology·2026
Same author

Risk of intensive care unit admission after immune checkpoint inhibitor use in cancer.

Seminars in oncology·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Gene expression profiling enhances Diffuse Large B cell lymphoma (DLBCL) classification, revealing subtypes and new therapeutic targets. This molecular approach improves understanding beyond traditional methods for better patient outcomes.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Diffuse Large B cell lymphoma (DLBCL) exhibits significant clinical heterogeneity not fully captured by standard diagnostic methods.
  • Current histopathologic and immunophenotypic evaluations are insufficient for precise DLBCL subclassification and outcome prediction.

Purpose of the Study:

  • To review the advancements in understanding DLBCL through gene expression profiling.
  • To highlight the potential of molecular profiling in improving lymphoma classification and identifying novel therapeutic strategies.

Main Methods:

  • Analysis of global gene expression patterns using DNA microarrays.
  • Molecular profiling of DLBCL samples to identify distinct subtypes.

Main Results:

Related Experiment Videos

  • Gene expression profiling offers improved classification of lymphomas, identifying specific DLBCL subtypes with distinct clinical behaviors.
  • This approach has led to the discovery of novel genes and a deeper understanding of aberrant signaling pathways in DLBCL.

Conclusions:

  • Molecular profiling, particularly gene expression profiling, is crucial for a more refined understanding of DLBCL.
  • These insights are paving the way for the development of targeted therapies for DLBCL subtypes.